Casdin Capital’s Evolent Health EVH Stock Holding History

Casdin Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-550,000	Closed	-$6.92M	–	32
2019 Q1	$6.92M	Hold	550,000	–	–	0.76%	25
2018 Q4	$11M	Hold	550,000	–	–	1.88%	21
2018 Q3	$15.6M	Hold	550,000	–	–	1.9%	20
2018 Q2	$11.6M	Sell	550,000 -560,000	-50%	-$10.6M	1.62%	20
2018 Q1	$15.8M	Buy	1,110,000 +32,500	+3%	+$465K	2.78%	17
2017 Q4	$13.3M	Buy	1,077,500 +282,500	+36%	+$3.98M	3.23%	15
2017 Q3	$14.2M	Buy	795,000 +275,000	+53%	+$5.67M	4%	14
2017 Q2	$13.2M	Hold	520,000	–	–	4.88%	5
2017 Q1	$11.6M	Sell	520,000 -35,000	-6%	-$672K	6.84%	6
2016 Q4	$8.21M	Buy	555,000 +170,000	+44%	+$3.35M	6.78%	5
2016 Q3	$9.48M	Buy	385,000 +145,500	+61%	+$3.4M	7.68%	4
2016 Q2	$4.6M	Buy	+239,500	New	+$3.29M	4.58%	9

Other funds holding EVH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Casdin Capital's EVH Position: Q2 2019 in Review

Casdin Capital sold out of Evolent Health (EVH) in Q2 2019, closing a stake of 550,000 shares — an estimated $6.92M sold.

Casdin Capital first reported a position in EVH in Q2 2016 and held it in 12 quarters. The position peaked at $15.8M in Q1 2018. 183 funds tracked by Wall St. Rank hold EVH as of Q2 2019.

Casdin Capital reported no remaining Evolent Health position as of Q2 2019 after selling out during the quarter.
Casdin Capital sold 550,000 Evolent Health shares in Q2 2019, an estimated $6.92M.
Casdin Capital first reported a position in Evolent Health in Q2 2016 and held it in 12 quarters.
Casdin Capital's Evolent Health position peaked at $15.8M in Q1 2018.
183 funds tracked by Wall St. Rank held Evolent Health as of Q2 2019.

Based on Casdin Capital's 13F filing for Q2 2019, filed 13 Aug 2019.